Loading...
Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
Sorafenib and lenvatinib are the only multikinase inhibitors (MKIs) approved for the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Although they have been demonstrated to improve progression free survival and overall response rate, the risk of toxicities is very...
Na minha lista:
| Udgivet i: | J Pers Med |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306329/ https://ncbi.nlm.nih.gov/pubmed/34357141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070674 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|